Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib combinations in advanced cancer
NCT02124148Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prexasertib in cancer, metastatic cancer, colorectal cancer (CRC) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose at Cycle 1. Started Jun 2014; status: completed.
02
Drugs
prexasertib
03
Conditions
cancermetastatic cancercolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT02124148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124148.